Table 2.
Interfering with tau deposition | Interfering with tau phosphorylation | Immunotherapy |
---|---|---|
Methylene blue: phase II trial (+) | Tau kinase inhibitors (lithium: phase I trial (−) in AD (+) in MCI ) | Vaccination: preclinical trials |
, encouraging results; −, disappointing results.
AD, Alzheimer’s disease; MCI, mild cognitive impairment.1